[go: up one dir, main page]

EP1004309A1 - Israpafant-containing water-base preparations - Google Patents

Israpafant-containing water-base preparations Download PDF

Info

Publication number
EP1004309A1
EP1004309A1 EP98921787A EP98921787A EP1004309A1 EP 1004309 A1 EP1004309 A1 EP 1004309A1 EP 98921787 A EP98921787 A EP 98921787A EP 98921787 A EP98921787 A EP 98921787A EP 1004309 A1 EP1004309 A1 EP 1004309A1
Authority
EP
European Patent Office
Prior art keywords
israpafant
agent
surfactant
aqueous
aqueous agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98921787A
Other languages
German (de)
French (fr)
Other versions
EP1004309A4 (en
Inventor
Tadashi Terai
Shinichi Yasueda
Takahiro Ogawa
Akira Otori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Mitsubishi Tanabe Pharma Corp
Original Assignee
Senju Pharmaceutical Co Ltd
Yoshitomi Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd, Yoshitomi Pharmaceutical Industries Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of EP1004309A1 publication Critical patent/EP1004309A1/en
Publication of EP1004309A4 publication Critical patent/EP1004309A4/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Definitions

  • the present invention relates to an aqueous agent containing israpafant. More particularly, the present invention relates to an aqueous solution obtained by dissolving israpafant in water at a high concentration and a suspension obtained by dispersing israpafant stably in water. These aqueous agents are utilized as an eye drop or nasal drop particularly effective for allergic conjunctivitis, allergic rhinitis and the like.
  • DE 42 01 147 A1 discloses that a compound having a PAF antagonistic action and having the formula is useful for allergic conjunctivitis and further for allergic rhinitis, and recites some formulation examples of oral suspension containing this compound.
  • israpafant is crystal or crystalline powder hardly soluble in water and easily dissolved in organic solvent such as dimethylformamide, methanol and the like. Nevertheless, the use of an organic solvent as a carrier of a preparation is inappropriate and, since in particular, an eye drop, a nasal drop and the like are locally administered to a site sensitive to irritation, the use of an organic solvent as a carrier to give an israpafant preparation should be avoided. As mentioned earlier, israpafant is hardly dissolved in water.
  • solubility in water at 25°C is less than 0.01 w/v%
  • solubility in buffer pH 4, 5, 6, 7, 8 and 9
  • detection limit 50 ng/ml
  • an object of the present invention is to provide an aqueous preparation obtained by dissolving israpafant at a high concentration, namely, at a concentration at which its efficacy can be fully exerted, and a suspension preparation which is less irritative and which is capable of fully exerting the efficacy of israpafant.
  • Another object of the present invention is to provide an aqueous solution of israpafant, which is obtained by dissolving israpafant at a high concentration, and a method for producing a suspension.
  • the present inventors have conducted intensive studies in an attempt to achieve the above-mentioned problems, and found that israpafant can be dissolved in water at a high concentration in the presence of a surfactant and that this aqueous solution can be used as an eye drop and a nasal drop, which resulted in the completion of the present invention.
  • the present inventors have further found that administration of israpafant as an aqueous suspension to a local site of the eye or nose is effective for allergic conjunctivitis, allergic rhinitis, vernal conjunctivitis, conjunctival allergy caused by contact lens (giant papillary conjunctivitis), phlyctenular conjunctivitis, contact blepharocon junctivitis, Sjögren's syndrome, multiple corneal infiltration, keratitis disciformis, stromal keratitis, endothelium keratitis, episcleritis, scleritis, uveitis, retinal vasculitis, papillary vasulitis, optic neuritis, eosinophilic granuloma, rejection associated with keratoplastry, eye itching, sneeze, nose itching, hypersensitivity of the nose, nose vestibule eczema, anterior rhinitis si
  • the present invention provides the following.
  • Israpafant which is used as the active ingredient of the aqueous agent of the present invention is a compound expressed by the formula (I)
  • concentration of israpafant (I) in the aqueous agent is appropriately determined, with preference given to not less than 0.01 w/v%.
  • the aqueous agent of the present invention is preferably used as an eye drop or a nasal drop.
  • the aqueous israpafant solution of the present invention can be produced by dissolving israpafant in water in the presence of a surfactant.
  • surfactant examples include cationic surfactants, anionic surfactants, nonionic surfactants and the like.
  • cationic surfactant examples include benzalkonium salt such as benzalkonium chloride (BAK) and the like.
  • anionic surfactant examples include sodium alkylsulfonate such as sodium dodecylsulfate (SDS), sodium pentanesulfonate, sodium octanesulfonate and the like.
  • the nonionic surfactant preferably has an HLB of 10 - 18 and a molecular weight of 500 - 4000, with preference given to ether nonionic surfactants and ester nonionic surfactants.
  • examples thereof include polyoxyethylene sorbitane fatty acid esters such as polysorbate 80 and the like, polyoxyethylene hydrogenated castor oil such as polyoxyethylene hydrogenated castor oil 60 (HCO 60) and the like, polyoxyethylene alkylphenyl formaldehyde condensate such as tyloxapol and the like, polyoxyethylene polyoxypropylene block copolymer such as poloxamer and the like, sucrose fatty acid ester and the like.
  • polyoxyethylene sorbitane fatty acid esters such as polysorbate 80 and the like
  • polyoxyethylene hydrogenated castor oil such as polyoxyethylene hydrogenated castor oil 60 (HCO 60) and the like
  • polyoxyethylene alkylphenyl formaldehyde condensate such as tyloxa
  • the above-mentioned surfactant can be used alone or in combination.
  • anionic surfactants cause irritation to the eye
  • a nonionic surfactant is preferably used concurrently to reduce irritation.
  • the concentration of israpafant in the aqueous solution is not less than 0.01 w/v%, preferably 0.01 - 0.1 w/v%.
  • concentration of israpafant is within the above-mentioned range, the local administration of an eye drop, a nasal drop and the like leads to exhibition of useful efficacy and preparation of an aqueous solution causing less irritation.
  • the surfactant is preferably contained in 0.5 - 10 w/v% of the aqueous solution, more preferably 0.5 - 4 w/v%.
  • the proportion of the surfactant relative to israpafant is preferably 30 - 80 parts by weight, more preferably 45 - 60 parts by weight, of a cationic surfactant, 3 - 10 parts by weight, more preferably 4 - 7 parts by weight, of an anionic surfactant, and 50 - 200 parts by weight, more preferably 70 - 160 parts by weight, of a nonionic surfactant, per part by weight of israpafant.
  • suspending agent examples include a nonionic surfactant, an anionic surfactant, a water soluble polymer and the like, which can be used alone or in combination.
  • the nonionic surfactant preferably has an HLB of 10 - 18 and a molecular weight of 500 - 4000, with preference given to an ether type nonionic surfactant and an ester type nonionic surfactant.
  • polyoxyethylene sorbitane fatty acid esters such as polysorbate 80 and the like
  • polyoxyethylene hydrogenated castor oil such as polyoxyethylene hydrogenated castor oil 60 (HCO 60) and the like
  • polyoxyethylene alkylphenyl formaldehyde condensate such as tyloxapol and the like
  • polyoxyethylene polyoxypropylene block copolymer such as poloxamer and the like
  • sucrose fatty acid ester and the like sucrose fatty acid ester and the like.
  • an anionic surfactant such as sodium lauryl sulfate (SDS) and the like can be used.
  • the water soluble polymer include water soluble cellulose derivatives such as hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose (CMC), methylcellulose (MC) and the like, carboxyvinyl polymer, macrogol, sodium chondroitin sulfate, polyvinylpyrrolidone such as polyvinylpyrrolidone K25 (PVP K25), polyvinylpyrrolidone K30 (PVP K30), polyvinylpyrrolidone K90 (PVP K90) and the like, polyvinyl alcohol and the like.
  • HPMC hydroxypropylmethylcellulose
  • CMC carboxymethylcellulose
  • MC methylcellulose
  • carboxyvinyl polymer macrogol, sodium chondroitin sulfate
  • polyvinylpyrrolidone such as polyvinylpyrrolidone K25 (PVP K25), polyvinylpyrrolidone K30 (PVP K30), polyvinylpyrrolidone K90 (PVP K90)
  • the concentration of israpafant in a suspension is generally 0.01 - 2 w/v%, preferably 0.1 - 1 w/v%.
  • concentration of israpafant is within the above-mentioned range, useful efficacy for local administration can be exerted and a stable suspension can be prepared.
  • the suspending agent is contained in a proportion of 0.00001 - 0.5 w/v% in a suspension.
  • the surfactant and water soluble polymer to be used as suspending agents can be used alone or in combination.
  • the concentration of each ingredient of the suspending agent is preferably 0.0001 - 0.1 w/v%, more preferably 0.001 - 0.1 w/v% and most preferably 0.005 - 0.1 w/v% in the case of a surfactant, and preferably 0.00001 - 0.5 w/v%, more preferably 0.0001 - 0.1 w/v% in the case of a water soluble polymer.
  • the proportion of israpafant and the surfactant is preferably 0.01 - 1 part by weight of a surfactant per part by weight of israpafant.
  • the proportion of israpafant and the water soluble polymer is preferably 0.0001 - 1 part by weight, more preferably 0.0005 - 0.1 part by weight, and most preferably 0.001 - 0.01 part by weight, of a water soluble polymer per part by weight of israpafant.
  • HPMC a weight ratio of 0.001 - 0.01 parts by weight per part by weight of israpafant is preferable.
  • concentration of the suspending agent is within the above-mentioned range, a stable suspension having fine dispersibility can be prepared.
  • the aqueous agent of the present invention can contain, where necessary, other anti-allergic agents, such as histamine release inhibitor, histamine receptor antagonist, leukotriene release inhibitor, leukotriene receptor antagonist, PAF release inhibitor, PAF receptor antagonist, IgE antibody production inhibitor, cytokine release inhibitor, cytokine receptor inhibitor and the like.
  • other anti-allergic agents such as histamine release inhibitor, histamine receptor antagonist, leukotriene release inhibitor, leukotriene receptor antagonist, PAF release inhibitor, PAF receptor antagonist, IgE antibody production inhibitor, cytokine release inhibitor, cytokine receptor inhibitor and the like.
  • aqueous agent of the present invention When the aqueous agent of the present invention is used as an eye drop or nasal drop, known additives typically used for an eye drop or a nasal drop can be used. Examples of such additive include isotonizing agent, buffer, chelating agent, preservative and the like.
  • isotonicity agent examples include inorganic salt such as sodium chloride, boric acid, potassium chloride and the like, and polyhydric alcohol such as glycerol, mannitol, sorbitol and the like.
  • the buffer may be, for example, borate buffer, phosphate buffer, acetate buffer, citrate buffer, Tris buffer, amino acid such as glutamine and ⁇ -aminocapronic acid, and the like.
  • Examples of chelating agent include disodium edetate, citric acid and the like.
  • Examples of preservative include quaternary ammonium salt such as benzalkonium chloride, benzetonium chloride and the like, p-aminobenzoate such as methyl p-aminobenzoate, ethyl p-aminobenzoate, propyl p-aminobenzoate, butyl p-aminobenzoate and the like, sorbic acid, chlorobutanol, disodium edetate, boric acid and the like.
  • an isotonicity agent is generally added in 0.5 - 6.5 w/v% of the aqueous agent
  • a buffer is generally added in 0.01 - 2 w/v% of the aqueous agent
  • a chelating agent is generally added in 0.001 - 1 w/v% of the aqueous agent
  • a preservative is generally added in 0.001 - 2 w/v% of the aqueous agent.
  • an aqueous solution can be obtained by various known methods.
  • a buffer, an isotonicity agent, a preservative and the like are added to sterile purified water for dissolution.
  • a surfactant and then israpafant are added, and they are dissolved, where necessary, the solution may be heated to about 70°C.
  • a pH adjusting agent hydroochloric acid, sodium hydroxide and the like is added to adjust the pH to a desired value.
  • israpafant may be dissolved in a 0.5 - 10 w/v% cationic surfactant or anionic surfactant, and a buffer, an isotonizing agent, a preservative and the like are added and dissolved, whereafter the mixture is lyophilized, which lyophilization product is dissolved when in use in an injectable distilled water and the like, or israpafant, a buffer, an isotonicity agent, a preservative and the like are mixed in a mortar and the like, sealed in a vial and the like and dissolved when in use in a liquid for dissolution containing a surfactant.
  • the method for preparing a dispersion is not particularly limited and can be a method conventionally known.
  • a suspending agent, a buffer, an isotonicity agent and a preservative are added to sterile purified water and dissolved, during which the mixture may be heated.
  • israpafant which is uniformly suspended in various homogenizers, mixers, mills or by ultrasonication.
  • pH is adjusted using a pH adjusting agent (hydrochloric acid, sodium hydroxide and the like) to give an aqueous dispersion.
  • aqueous agent of the present invention is used as an eye drop or nasal drop for the treatment of, for example, allergic conjunctivitis, allergic rhinitis, vernal conjunctivitis, conjunctival allergy caused by contact lens (giant papillary conjunctivitis), phlyctenular conjunctivitis, contact blepharocon junctivitis, Sjögren's syndrome, multiple corneal infiltration, keratitis disciformis, stromal keratitis, endothelium keratitis, episcleritis, scleritis, uveitis, retinal vasculitis, papillary vasulitis, optic neuritis, eosinophilic granuloma, rejection associated with keratoplastry, eye itching, sneeze, nose itching, hypersensitivity of the nose, nose vestibule eczema, anterior rhinitis sicca, nasal obstruction and the
  • inventive agent with other anti-allergic, anti-inflammatory and/or anti-bacterial eye drop, nasal drop and the like.
  • Israpafant manufactured by Yoshitomi Pharmaceutical Industries, Ltd. was suspended in 0.1% acetate buffer (pH 4, 5, 6), phosphate buffer (pH 6, 7, 8) and borate buffer (pH 8, 9) in a concentration of 0.1% (w/v%, hereinafter the same). Each suspension was filled in a glass ampoule by 5 ml and shaken at 25°C overnight (ca. 15 hours). After passing through a 0.45 ⁇ m membrane filter, the solubility of israpafant was measured by HPLC.
  • the solubility of the above-mentioned israpafant in each buffer is shown in Table 1, and the solubility in an aqueous solution containing various additives is shown in Table 2.
  • buffer pH of buffer solubility ( ⁇ g/ml) acetate buffer pH 4 0.0 acetate buffer pH 5 0.0 acetate buffer pH 6 0.0 phosphate buffer pH 6 0.0 phosphate buffer pH 7 0.0 phosphate buffer pH 8 0.0 borate buffer pH 8 0.0 borate buffer pH 9 0.0 additive solubility ( ⁇ g/ml) surfactant polysorbate 80 66.9 polysorbate 80 (4% aq.
  • israpafant in each buffer was below detection limit (50 ng/ml) by HPLC.
  • Israpafant did not dissolve in an aqueous solution containing a water soluble polymer or cyclodextrin. However, it dissolved well in an aqueous surfactant solution. Particularly, israpafant dissolved extremely well in a 4% aqueous polysorbate solution and a 0.5% aqueous sodium dodecylsulfate solution.
  • Israpafant manufactured by Yoshitomi Pharmaceutical Industries, Ltd.
  • a vehicle pH 5
  • a suspension of israpafant in 0.5% CMC at 10 mg/ml was prepared for oral administration.
  • physiological saline was used as a control.
  • Polysorbate 80 0.1 g sodium dihydrogenphosphate ⁇ 2H 2 O 0.1 g sodium chloride 0.9 g distilled water 100 ml in total
  • Guinea pigs were sensitized with a dispersion of 10 ⁇ g ovalbumin (OA) and 30 mg aluminum hydroxide gel by peritoneal administration. At 14 days after the sensitization, a 2.5% OA antigen solution was instilled into the both eyes by 10 ⁇ l to induce allergic conjunctivitis (first challenge). At 20 minutes after the last challenge, conjunctivitis signs were observed and the animals were grouped in such a manner that the severity of the condition was equalized from the degrees of chemosis, conjunctival injection and tearing.
  • OA ovalbumin
  • the evaluation of a drug included the following steps. At 24 hours from the first challenge, 10 mg/kg Evans' blue was intravenously administered, and a 2.5% OA antigen solution was instilled into the both eyes by 10 ⁇ l to again induce conjunctivitis (the second challenge). Thirty minutes later, conjunctival dye-leakage part was excised, the parts of the both eyes were combined and the amount of the leaked dye was measured. The drug was instilled into the both eyes by 10 ⁇ l at 3, 2, 1 hour before the second challenge in the case of administration by instillation. In the case of an oral administration, 10 mg/kg was administered once at 1 hour before the second challenge. For suppression of histamine reaction, 1 mg/kg of mepyramine was intravenously administered one minute before.
  • the drug was evaluated by removing the eye ball at 6 hours after the second challenge, preparing an optical microscopic specimen according to a conventional method, staining eosinophils by Luna staining, and counting and averaging the number of eosinophils infiltrated into conjunctiva with regard to each of 6 visible areas (one visible area being 0.04 mm 2 ) of the vicinity of conjunctival lymphoid tissue.
  • the drug was administered in the same manner as in 1).
  • the dye-leakage ( ⁇ g/two eye balls) of the control group instilled with physiological saline was 34.5 ⁇ g but that of the israpafant instillation group and oral administration group was 24.7 ⁇ g and 25.3 ⁇ g, respectively. Thus, they did not show a significant suppressive effect.
  • the dye-leakage of the mepyramine administration group was 17.5 ⁇ g, thus showing significant suppression of promotion of vascular permeability.
  • concurrent instillation group and oral concurrent group showed less (11.0 ⁇ g and 10.1 ⁇ g, respectively) dye-leakage than the single administration group, thus significantly suppressing promotion of vascular permeability.
  • israpafant was useful against early phase reaction when used concurrently with an antihistamic agent, because PAF is involved in the early phase reaction of allergic conjunctivitis.
  • Fig. 3 The total score of conjunctivitis signs at 20 minutes after the second challenge is shown in Fig. 3.
  • Fig. 4 The conjunctival eosinophil infiltration count at 6 hours after the second challenge is shown in Fig. 4.
  • the eosinophil infiltration count (cell/0.04 mm 2 ) of the control group was 95.3, but it was 71.8 in the israpafant instillation group, showing significant suppression of eosinophil infiltration.
  • the oral group showed no suppressive effect.
  • the mepyramine group, the concurrent instillation group and concurrent oral administration group showed suppressive effect, but the effect of each group was almost the same, and no effect from the concurrent use of israpafant was found.
  • Israpafant was suspended at 0.03, 0.1, 0.3 and 1.0%.
  • Physiological saline was used for the control group.
  • the formulation of the vehicle for an israpafant eye drop was as shown below, wherein the pH of the eye drop at each concentration was 7.0.
  • sodium dihydrogenphosphate ⁇ 2H 2 O 0.1 g sodium chloride 0.9 g polysorbate 80 0.1 g distilled water 100 ml in total
  • PAF diluted to 4 ⁇ g/ml was administered to the upper subconjunctiva of the rat by 25 ⁇ l and at the same time, 0.5% Evans' blue (0.5 ml) was intravenously administered. Thirty minutes later, the dye-leakage part of the conjunctiva was excised and the dye was extracted with formamide, after which absorbance (625 nm) was measured. The test drug was administered by instillation (5 ⁇ l) to the eye at 1, 2 hours before subconjunctival induction of PAF.
  • the dye-leakage of the control group was 40.0 ⁇ g/site but israpafant showed a concentration-dependent suppressive effect, wherein the suppressive percentage at 0.03% - 1.0% concentration was 19.1%, 29.6%, 41.6% and 53.2%, showing significant difference at a concentration of 0.1% or greater. From the above results, israpafant showed a concentration-dependent suppressive effect against promotion of vascular permeability at conjunctival local site by PAF, demonstrating good penetration into a tissue of the present preparation.
  • Polysorbate 80 used met the standard of the Japan Pharmacopoeia.
  • the following israpafant suspension formulation was prepared. Polysorbate 80 was used as the suspending agent, phosphate buffer (pH 7) was used as the buffer, and sodium chloride was used as the isotonizing agent. The suspension was filled in glass ampoules by 5 ml and stored at 25, 40 and 60°C. The suspension was sampled with time (3 days later, one week later, 2 weeks later) and israpafant content was quantitatively determined by HPLC. israpafant 0.1 g polysorbate 80 0.1 g sodium dihydrogenphosphate ⁇ 2H 2 O 0.1 g sodium chloride 0.9 g distilled water 100 ml in total
  • the 0.1% israpafant suspension after storage at 60°C for 2 weeks showed an israpafant residual content of 100.3%.
  • sodium dodecylsulfate, polysorbate 80, sodium dihydrogenphosphate dihydrate, boric acid and benzalkonium chloride were dissolved in sterile purified water.
  • a pH adjusting agent the pH was adjusted to about 7.
  • Israpafant was added and the mixture was heated to about 70°C to allow dissolution. After cooling, the pH adjusting agent was used again to adjust the pH 7 to give an eye drop.
  • Example 2 Using the following ingredients and in the same manner as in Example 1, a nasal drop was obtained. israpafant 0.05 g polysorbate 80 4.0 g sodium dihydrogenphosphate dihydrate 0.1 g sodium chloride 0.9 g benzalkonium chloride 0.01 g sodium hydroxide q.s. sterile purified water amount to make the total amount 100 ml pH 8.0
  • Example 2 Using the following ingredients and in the same manner as in Example 1, an eye drop was obtained. israpafant 0.05 g sodium octanesulfonate 0.5 g polysorbate 80 3.35 g sodium dihydrogenphosphate dihydrate 0.1 g sodium chloride 0.9 g benzalkonium chloride 0.005 g sodium hydroxide q.s. sterile purified water amount to make the total amount 100 ml pH 7.0
  • Example 2 Using the following ingredients and in the same manner as in Example 1, an eye drop was obtained. israpafant 0.05 g sodium pentanesulfonate 0.5 g polysorbate 80 4.15 g sodium dihydrogenphosphate dihydrate 0.1 g conc. glycerol 2.6 g benzalkonium chloride 0.005 g sodium hydroxide q.s. sterile purified water amount to make the total amount 100 ml pH 7.0
  • israpafant 1.0 g HPMC 0.001 g sodium dihydrogenphosphate dihydrate 0.1 g sodium chloride 0.9 g benzalkonium chloride 0.005 g sodium hydroxide appropriate amount sterile purified water amount to make the total amount 100 ml pH 7.0
  • israpafant 1.0 g HPMC 0.01 g boric acid 1.6 g benzalkonium chloride 0.005 g sodium hydroxide appropriate amount sterile purified water amount to make the total amount 100 ml pH 7.0
  • israpafant 1.0 g methylcellulose 0.001 g sodium dihydrogenphosphate dihydrate 0.1 g sodium chloride 0.9 g benzalkonium chloride 0.005 g sodium hydroxide appropriate amount sterile purified water amount to make the total amount 100 ml pH 7.0
  • the aqueous agent of the present invention shows superior therapeutic effect when locally administered as an eye drop or a nasal drop for allergic conjunctivitis, allergic rhinitis, venal conjunctivitis, conjunctival allergy caused by contact lens (giant papillary conjunctivitis), phlyctenular conjunctivitis, contact blepharoconjunctivitis, Sjögren's syndrome, multiple corneal infiltration, keratitis disciformis, stromal keratitis, endothelium keratitis, episcleritis, scleritis, uveitis, retinal vasculitis, papillary vasulitis, optic neuritis, eosinophilic granuloma, rejection associated with keratoplastry, eye itching, sneeze, nose itching, hypersensitivity of the nose, nose vestibule eczema, anterior rhinitis sicca, nasal obstruction and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Figure 80000001
Water-base preparations comprising an aqueous solution or suspension of israpafant represented by structural formula (I) and providing eye drops and nose drugs exhibiting excellent therapeutic effects against allergic conjunctivitis and rhinitis by local administration.

Description

Technical Field
The present invention relates to an aqueous agent containing israpafant. More particularly, the present invention relates to an aqueous solution obtained by dissolving israpafant in water at a high concentration and a suspension obtained by dispersing israpafant stably in water. These aqueous agents are utilized as an eye drop or nasal drop particularly effective for allergic conjunctivitis, allergic rhinitis and the like.
Background Art
4-(2-Chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine (general name israpafant) disclosed in JP-B-5-55510 and having the formula (I)
Figure 00010001
is known to show superior antagonistic action against platelet activating factor (PAF). Therefore, it is considered to be extremely useful for many diseases induced by PAF, such as inflammatory diseases, allergic diseases, anaphylactic shock, septic shock, vascular diseases such as DIC and the like, cardiac diseases, asthma, pulmonary edema, adult respiratory diseases, ulcer and the like.
In addition, DE 42 01 147 A1 discloses that a compound having a PAF antagonistic action and having the formula
Figure 00020001
is useful for allergic conjunctivitis and further for allergic rhinitis, and recites some formulation examples of oral suspension containing this compound.
However, there is no disclosure of an aqueous preparation obtained by dissolving israpafant in water.
That is, israpafant is crystal or crystalline powder hardly soluble in water and easily dissolved in organic solvent such as dimethylformamide, methanol and the like. Nevertheless, the use of an organic solvent as a carrier of a preparation is inappropriate and, since in particular, an eye drop, a nasal drop and the like are locally administered to a site sensitive to irritation, the use of an organic solvent as a carrier to give an israpafant preparation should be avoided. As mentioned earlier, israpafant is hardly dissolved in water. Specifically, its solubility in water at 25°C is less than 0.01 w/v%, and the solubility in buffer ( pH 4, 5, 6, 7, 8 and 9) is below detection limit (50 ng/ml) by HPLC, at such low concentration the efficacy of israpafant cannot be exerted in any way.
While to be mentioned later, when an israpafant suspension was orally administered to a guinea pig suffering from allergic conjunctivitis, no effect was observed in the test by the present inventors.
Therefore, there is a demand for an israpafant preparation which is effective for allergic conjunctivitis and further for allergic rhinitis.
Disclosure of the Invention
It is therefore an object of the present invention to provide an aqueous agent containing israpafant, which is particularly effective against allergic conjunctivitis, allergic rhinitis and the like.
In particularl, an object of the present invention is to provide an aqueous preparation obtained by dissolving israpafant at a high concentration, namely, at a concentration at which its efficacy can be fully exerted, and a suspension preparation which is less irritative and which is capable of fully exerting the efficacy of israpafant.
Another object of the present invention is to provide an aqueous solution of israpafant, which is obtained by dissolving israpafant at a high concentration, and a method for producing a suspension.
The present inventors have conducted intensive studies in an attempt to achieve the above-mentioned problems, and found that israpafant can be dissolved in water at a high concentration in the presence of a surfactant and that this aqueous solution can be used as an eye drop and a nasal drop, which resulted in the completion of the present invention.
The present inventors have further found that administration of israpafant as an aqueous suspension to a local site of the eye or nose is effective for allergic conjunctivitis, allergic rhinitis, vernal conjunctivitis, conjunctival allergy caused by contact lens (giant papillary conjunctivitis), phlyctenular conjunctivitis, contact blepharocon junctivitis, Sjögren's syndrome, multiple corneal infiltration, keratitis disciformis, stromal keratitis, endothelium keratitis, episcleritis, scleritis, uveitis, retinal vasculitis, papillary vasulitis, optic neuritis, eosinophilic granuloma, rejection associated with keratoplastry, eye itching, sneeze, nose itching, hypersensitivity of the nose, nose vestibule eczema, anterior rhinitis sicca, nasal obstructioin and the like, and further that, since israpafant is a compound hardly soluble in water, it can be prepared into a stable aqueous eye drop or nasal drop suspension, which is free of agglomeration or caking of suspended particles, which resulted in the completion of the present invention.
Accordingly, the present invention provides the following.
  • (1) An aqueous agent containing israpafant, which is expressed by the formula (I):
    Figure 00040001
  • (2) The aqueous agent of (1) above, wherein the israpafant (I) has a concentration of not less than 0.01 w/v%.
  • (3) The aqueous agent of (2) above, wherein the aqueous agent is an eye drop or nasal drop.
  • (4) The aqueous agent of (3) above, wherein the eye drop or nasal drop is an aqueous solution containing israpafant (I).
  • (5) The aqueous agent of (4) above, wherein the israpafant (I) has a concentration of 0.01 - 0.1 w/v%.
  • (6) The aqueous agent of (5) above, further comprising a surfactant.
  • (7) The aqueous agent of (6) above, wherein the surfactant has a concentration of 0.5 - 10 w/v%.
  • (8) The aqueous agent of (7) above, wherein the surfactant is at least one member selected from the group consisting of a cationic surfactant, an anionic surfactant and a nonionic surfactant.
  • (9) The aqueous agent of (3) above, wherein the eye drop or nasal drop is a suspension containing israpafant (I).
  • (10) The aqueous agent of (9) above, wherein the israpafant has a concentration of 0.01 - 2 w/v%.
  • (11) The aqueous agent of (10) above, further comprising a suspending agent.
  • (12) The aqueous agent of (11) above, wherein the suspending agent is at least one member selected from a surfactant and a water soluble polymer.
  • (13) The aqueous agent of (12) above, wherein the surfactant has a concentration of 0.0001 - 0.1 w/v%.
  • (14) The aqueous agent of (13) above, wherein the surfactant is at least one surfactant selected from a nonionic surfactant and an anionic surfactant.
  • (15) The aqueous agent of (12) above, wherein the water soluble polymer has a concentration of 0.00001 - 0.5 w/v%.
  • (16) The aqueous agent of (15) above, wherein the water soluble polymer is a water soluble cellulose derivative.
  • (17) The aqueous agent of (16) above, wherein the water soluble cellulose derivative is at least one cellulose derivative selected from hydroxypropylmethylcellulose, carboxymethylcellulose and methylcellulose.
  • (18) The aqueous agent of (17) above, wherein the agent contains israpafant (I) in a proportion of 0.1 - 1 w/v% and hydroxypropyl methylcellulose in the weight ratio to israpafant (I) of 0.001 - 0.01:1.
  • (19) A method for producing an aqueous solution of israpafant, comprising dissolving israpafant of the formula (I):
    Figure 00050001
    in water in the presence of a surfactant.
  • (20) A method for producing a suspension of israpafant, comprising suspending israpafant of the formula (I):
    Figure 00050002
    in water in the presence of a suspending agent.
    • Israpafant which is used as the active ingredient of the aqueous agent of the present invention is a compound expressed by the formula (I)
    Figure 00060001
    The concentration of israpafant (I) in the aqueous agent is appropriately determined, with preference given to not less than 0.01 w/v%. The aqueous agent of the present invention is preferably used as an eye drop or a nasal drop.
    The aqueous israpafant solution of the present invention can be produced by dissolving israpafant in water in the presence of a surfactant.
    Examples of the surfactant include cationic surfactants, anionic surfactants, nonionic surfactants and the like.
    Examples of the cationic surfactant include benzalkonium salt such as benzalkonium chloride (BAK) and the like.
    Examples of the anionic surfactant include sodium alkylsulfonate such as sodium dodecylsulfate (SDS), sodium pentanesulfonate, sodium octanesulfonate and the like.
    The nonionic surfactant preferably has an HLB of 10 - 18 and a molecular weight of 500 - 4000, with preference given to ether nonionic surfactants and ester nonionic surfactants. Examples thereof include polyoxyethylene sorbitane fatty acid esters such as polysorbate 80 and the like, polyoxyethylene hydrogenated castor oil such as polyoxyethylene hydrogenated castor oil 60 (HCO 60) and the like, polyoxyethylene alkylphenyl formaldehyde condensate such as tyloxapol and the like, polyoxyethylene polyoxypropylene block copolymer such as poloxamer and the like, sucrose fatty acid ester and the like.
    The above-mentioned surfactant can be used alone or in combination. In particular, since anionic surfactants cause irritation to the eye, when an aqueous solution containing an anionic surfactant is used as an eye drop, a nonionic surfactant is preferably used concurrently to reduce irritation.
    The concentration of israpafant in the aqueous solution is not less than 0.01 w/v%, preferably 0.01 - 0.1 w/v%. When the concentration of israpafant is within the above-mentioned range, the local administration of an eye drop, a nasal drop and the like leads to exhibition of useful efficacy and preparation of an aqueous solution causing less irritation.
    When dissolving israpafant in water in the above-mentioned range, the surfactant is preferably contained in 0.5 - 10 w/v% of the aqueous solution, more preferably 0.5 - 4 w/v%.
    The proportion of the surfactant relative to israpafant is preferably 30 - 80 parts by weight, more preferably 45 - 60 parts by weight, of a cationic surfactant, 3 - 10 parts by weight, more preferably 4 - 7 parts by weight, of an anionic surfactant, and 50 - 200 parts by weight, more preferably 70 - 160 parts by weight, of a nonionic surfactant, per part by weight of israpafant.
    Examples of the suspending agent to be used when preparing israpafant into an aqueous suspension in the present invention include a nonionic surfactant, an anionic surfactant, a water soluble polymer and the like, which can be used alone or in combination.
    The nonionic surfactant preferably has an HLB of 10 - 18 and a molecular weight of 500 - 4000, with preference given to an ether type nonionic surfactant and an ester type nonionic surfactant.
    Specific examples include polyoxyethylene sorbitane fatty acid esters such as polysorbate 80 and the like, polyoxyethylene hydrogenated castor oil such as polyoxyethylene hydrogenated castor oil 60 (HCO 60) and the like, polyoxyethylene alkylphenyl formaldehyde condensate such as tyloxapol and the like, polyoxyethylene polyoxypropylene block copolymer such as poloxamer and the like, sucrose fatty acid ester and the like. In addition, an anionic surfactant such as sodium lauryl sulfate (SDS) and the like can be used.
    Preferable examples of the water soluble polymer include water soluble cellulose derivatives such as hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose (CMC), methylcellulose (MC) and the like, carboxyvinyl polymer, macrogol, sodium chondroitin sulfate, polyvinylpyrrolidone such as polyvinylpyrrolidone K25 (PVP K25), polyvinylpyrrolidone K30 (PVP K30), polyvinylpyrrolidone K90 (PVP K90) and the like, polyvinyl alcohol and the like.
    The concentration of israpafant in a suspension is generally 0.01 - 2 w/v%, preferably 0.1 - 1 w/v%. When the concentration of israpafant is within the above-mentioned range, useful efficacy for local administration can be exerted and a stable suspension can be prepared.
    The suspending agent is contained in a proportion of 0.00001 - 0.5 w/v% in a suspension. The surfactant and water soluble polymer to be used as suspending agents can be used alone or in combination.
    The concentration of each ingredient of the suspending agent is preferably 0.0001 - 0.1 w/v%, more preferably 0.001 - 0.1 w/v% and most preferably 0.005 - 0.1 w/v% in the case of a surfactant, and preferably 0.00001 - 0.5 w/v%, more preferably 0.0001 - 0.1 w/v% in the case of a water soluble polymer.
    The proportion of israpafant and the surfactant is preferably 0.01 - 1 part by weight of a surfactant per part by weight of israpafant. The proportion of israpafant and the water soluble polymer is preferably 0.0001 - 1 part by weight, more preferably 0.0005 - 0.1 part by weight, and most preferably 0.001 - 0.01 part by weight, of a water soluble polymer per part by weight of israpafant. Particularly, when HPMC is used, a weight ratio of 0.001 - 0.01 parts by weight per part by weight of israpafant is preferable. When the concentration of the suspending agent is within the above-mentioned range, a stable suspension having fine dispersibility can be prepared.
    The aqueous agent of the present invention can contain, where necessary, other anti-allergic agents, such as histamine release inhibitor, histamine receptor antagonist, leukotriene release inhibitor, leukotriene receptor antagonist, PAF release inhibitor, PAF receptor antagonist, IgE antibody production inhibitor, cytokine release inhibitor, cytokine receptor inhibitor and the like.
    When the aqueous agent of the present invention is used as an eye drop or nasal drop, known additives typically used for an eye drop or a nasal drop can be used. Examples of such additive include isotonizing agent, buffer, chelating agent, preservative and the like.
    Examples of isotonicity agent include inorganic salt such as sodium chloride, boric acid, potassium chloride and the like, and polyhydric alcohol such as glycerol, mannitol, sorbitol and the like.
    The buffer may be, for example, borate buffer, phosphate buffer, acetate buffer, citrate buffer, Tris buffer, amino acid such as glutamine and ε-aminocapronic acid, and the like.
    Examples of chelating agent include disodium edetate, citric acid and the like. Examples of preservative include quaternary ammonium salt such as benzalkonium chloride, benzetonium chloride and the like, p-aminobenzoate such as methyl p-aminobenzoate, ethyl p-aminobenzoate, propyl p-aminobenzoate, butyl p-aminobenzoate and the like, sorbic acid, chlorobutanol, disodium edetate, boric acid and the like.
    The amounts of these additives are subject to no particular limitation, but an isotonicity agent is generally added in 0.5 - 6.5 w/v% of the aqueous agent, a buffer is generally added in 0.01 - 2 w/v% of the aqueous agent, a chelating agent is generally added in 0.001 - 1 w/v% of the aqueous agent, and a preservative is generally added in 0.001 - 2 w/v% of the aqueous agent.
    The method for preparing an aqueous solution is subject to no particular limitation, and an aqueous solution can be obtained by various known methods. For example, a buffer, an isotonicity agent, a preservative and the like are added to sterile purified water for dissolution. Thereto are added a surfactant and then israpafant, and they are dissolved, where necessary, the solution may be heated to about 70°C. After cooling, a pH adjusting agent (hydrochloric acid, sodium hydroxide and the like) is added to adjust the pH to a desired value.
    Alternatively, israpafant may be dissolved in a 0.5 - 10 w/v% cationic surfactant or anionic surfactant, and a buffer, an isotonizing agent, a preservative and the like are added and dissolved, whereafter the mixture is lyophilized, which lyophilization product is dissolved when in use in an injectable distilled water and the like, or israpafant, a buffer, an isotonicity agent, a preservative and the like are mixed in a mortar and the like, sealed in a vial and the like and dissolved when in use in a liquid for dissolution containing a surfactant.
    The method for preparing a dispersion is not particularly limited and can be a method conventionally known. For example, a suspending agent, a buffer, an isotonicity agent and a preservative are added to sterile purified water and dissolved, during which the mixture may be heated. To this solution is added israpafant, which is uniformly suspended in various homogenizers, mixers, mills or by ultrasonication. Then, pH is adjusted using a pH adjusting agent (hydrochloric acid, sodium hydroxide and the like) to give an aqueous dispersion.
    When the aqueous agent of the present invention thus prepared is used as an eye drop or nasal drop for the treatment of, for example, allergic conjunctivitis, allergic rhinitis, vernal conjunctivitis, conjunctival allergy caused by contact lens (giant papillary conjunctivitis), phlyctenular conjunctivitis, contact blepharocon junctivitis, Sjögren's syndrome, multiple corneal infiltration, keratitis disciformis, stromal keratitis, endothelium keratitis, episcleritis, scleritis, uveitis, retinal vasculitis, papillary vasulitis, optic neuritis, eosinophilic granuloma, rejection associated with keratoplastry, eye itching, sneeze, nose itching, hypersensitivity of the nose, nose vestibule eczema, anterior rhinitis sicca, nasal obstruction and the like, it is preferably administered 2 - 6 times a day by 20 - 50 µl per dose.
    It is also possible to concurrently use the inventive agent with other anti-allergic, anti-inflammatory and/or anti-bacterial eye drop, nasal drop and the like.
    Brief Description of the Drawings
  • Fig. 1 is a photograph (biological morphology) showing the standard for grouping of guinea pigs for the evaluation of suppressive effect (early phase reaction) against promotion of conjunctival vascular permeability in Experimental Example 2; Fig. 2 shows conjunctival dye-leakage at 30 minutes after the second challenge for the evaluation of suppressive effect against promotion of conjunctival vascular permeability in Experimental Example 2; Fig. 3 shows scores of conjunctivitis at 20 minutes after the second challenge for the evaluation of suppressive effect against immediate allergic conjunctivitis in Experimental Example 2; and Fig. 4 shows number of conjunctival eosinophil infiltration at 6 hours after the second challenge for the evaluation of suppressive effect against conjunctival eosinophil infiltration in Experimental Example 2.
    • Best Mode of Embodying the Invention
    The present invention is explained in detail in the following by way of Examples and Experimental Examples, to which the present invention is not limited.
    The dissolution test of israpafant is shown in the following.
    Experimental Example 1
    Israpafant (manufactured by Yoshitomi Pharmaceutical Industries, Ltd.) was suspended in 0.1% acetate buffer ( pH 4, 5, 6), phosphate buffer (pH 6, 7, 8) and borate buffer (pH 8, 9) in a concentration of 0.1% (w/v%, hereinafter the same). Each suspension was filled in a glass ampoule by 5 ml and shaken at 25°C overnight (ca. 15 hours). After passing through a 0.45 µm membrane filter, the solubility of israpafant was measured by HPLC.
    In 0.1% phosphate buffer (pH 7) were dissolved the additives shown in Table 2 in a proportion of 0.5% (0.5% and 4% in the sole case of polysorbate). In the same manner as above, israpafant was suspended and dissolved, after which the solubility of israpafant was measured by HPLC.
    Quantitative Determination of israpafant - by HPLC HPLC conditions
  • column: YMC AM-302 (4.6×150 mm)
  • mobile phase: acetonitrile:0.1M ammonium acetate-87:13
  • detection: UV 244 nm
  • column temperature:35°C
  • flow rate: 0.7 ml/min
  • internal standard:1,3,5-triphenylbenzene
    • The solubility of the above-mentioned israpafant in each buffer is shown in Table 1, and the solubility in an aqueous solution containing various additives is shown in Table 2.
    buffer pH of buffer solubility (µg/ml)
    acetate buffer pH 4 0.0
    acetate buffer pH 5 0.0
    acetate buffer pH 6 0.0
    phosphate buffer pH 6 0.0
    phosphate buffer pH 7 0.0
    phosphate buffer pH 8 0.0
    borate buffer pH 8 0.0
    borate buffer pH 9 0.0
    additive solubility (µg/ml)
    surfactant
    polysorbate
    80 66.9
    polysorbate 80 (4% aq. solution) 581.1
    HCO60 47.3
    BAK 99.0
    SDS 1057.0
    Tyloxapol 29.5
    water soluble polymer
    HPMC 0.6
    PVP(K30) 0.0
    PVA(EG40) 0.4
    CMC Na 0.0
    chondroitin sulfate 0.0
    PEG-1000 0.0
    PEG-4000 0.0
    cyclodextrin
    α-CD 0.0
    β-CD 0.0
    γ-CD 0.0
    2HP-β-CD 0.0
    Others
    caffeine 0.0
    propylene glycol 0.0
    2-pyrrolidone 0.0
    Each symbol in Table 2 is as follows.
  • HCO60:polyoxyethylene hydrogenated castor oil 60
  • BAK:benzalkonium chloride
  • SDS:sodium dodecylsulfate
  • HPMC:hydroxypropylmethylcellulose
  • PVP:polyvinylpyrrolidone
  • PVA:polyvinyl alcohol
  • CMC Na:sodium carboxymethylcellulose
  • PEG:polyethylene glycol
  • CD:cyclodextrin
    • The solubility of israpafant in each buffer was below detection limit (50 ng/ml) by HPLC. Israpafant did not dissolve in an aqueous solution containing a water soluble polymer or cyclodextrin. However, it dissolved well in an aqueous surfactant solution. Particularly, israpafant dissolved extremely well in a 4% aqueous polysorbate solution and a 0.5% aqueous sodium dodecylsulfate solution.
    The effect of the eye drop of the present invention against allergic conjunctivitis, which is an ocular inflammation, is shown in the following.
    Experimental Example 2 1. Object
    The suppressive effect of israpafant against guinea pig active sensitization allergic conjunctivitis was studied.
    In allergic conjunctivitis, an early phase reaction that occurs 10 - 20 minutes after antigen challenge and late phase reaction that occurs 4-10 hours later have been clinically confirmed. In the former, histamine, leukotriene, PAF and the like liberated from mast cells are involved and conjunctivitis signs of itching, chemosis, injection and tearing are observed. In the latter, chemical mediators such as histamine, leukotriene, PAF and the like, and cytokine such as interleukin 3, interleukin 5 and the like are also involved, wherein edema and foreign body sensation are observed. It is said that eosinophils and lymphocytes infiltrate into conjunctiva and cause epithelial disorders at cornea and conjunctiva due to injurious proteins in eosinophil granules.
    For investigation of usefulness of israpafant against allergic conjunctivitis, its suppressive effect against allergic conjunctivitis by guinea pig active sensitization was studied.
    In this model with regard to the early phase reaction, promotion of conjunctival vascular permeability and signs of conjunctivitis were the index of evaluation, and for the late phase reaction, eosinophil infiltration into conjunctiva was the index of evaluation.
    2. Animals used
    Male Hartley guinea pigs weighing about 300 g purchased from Japan SLC. Ltd. were used. These animals had free access to a solid feed (γ ray irradiated feed LRC4, ORIENTAL YEAST CO., LTD.) and tap water, and were bred in a breeding chamber set to a temperature 23 ±2°C and humidity 55±15%.
    3. Test drug
    Israpafant (manufactured by Yoshitomi Pharmaceutical Industries, Ltd.) was suspended in a vehicle (pH 5) shown below at a concentration of 1% to give an eye drop suspension. In addition, a suspension of israpafant in 0.5% CMC at 10 mg/ml was prepared for oral administration. As a control, physiological saline was used.
    Polysorbate 80 0.1 g
    sodium dihydrogenphosphate·2H2O 0.1 g
    sodium chloride 0.9 g
    distilled water 100 ml in total
    4. Test method 1) Suppressive effect (early phase reaction) against promotion of conjunctival vascular permeability
    Guinea pigs were sensitized with a dispersion of 10 µg ovalbumin (OA) and 30 mg aluminum hydroxide gel by peritoneal administration. At 14 days after the sensitization, a 2.5% OA antigen solution was instilled into the both eyes by 10 µl to induce allergic conjunctivitis (first challenge). At 20 minutes after the last challenge, conjunctivitis signs were observed and the animals were grouped in such a manner that the severity of the condition was equalized from the degrees of chemosis, conjunctival injection and tearing.
    The evaluation of a drug included the following steps. At 24 hours from the first challenge, 10 mg/kg Evans' blue was intravenously administered, and a 2.5% OA antigen solution was instilled into the both eyes by 10 µl to again induce conjunctivitis (the second challenge). Thirty minutes later, conjunctival dye-leakage part was excised, the parts of the both eyes were combined and the amount of the leaked dye was measured. The drug was instilled into the both eyes by 10 µl at 3, 2, 1 hour before the second challenge in the case of administration by instillation. In the case of an oral administration, 10 mg/kg was administered once at 1 hour before the second challenge. For suppression of histamine reaction, 1 mg/kg of mepyramine was intravenously administered one minute before.
    2) Suppressive effect (early phase reaction) against immediate allergic conjunctivitis signs
    In the same manner as in 1), sensitization and induction by the first challenge and the second challenge were performed. Twenty minutes later, conjunctivitis signs were observed, and chemosis was scored 0 - 6 points [see Fig. 1, A:0, B:2 (weak), C:4 (moderate), D:6 (strong)], conjunctival injection was scored 0 - 4 points (0: no injection, 1: very mild injection in the eye lid or bulbar conjunctiva, 2: mild injection in the eye lid or bulbar conjunctiva, 3: strong injection in the eye lid or bulbar conjunctiva, 4: strong injection in a wide area of the eye lid and bulbar conjunctiva), and tearing was scored 0 - 4 points (0: no tearing, 1: extremely small amount of tearing, 2: tearing, 3: a small amount of secretion, 4: a large amount of secretion), wherein evaluation followed the total scores. The drug was administered by instillation (10 µl) into one eye at 2, 4, 8 hours after the first challenge and 3, 2, 1 hour before the second challenge.
    3) Suppressive effect (early phase reaction) against eosinophil infiltration into conjunctiva
    In the same manner as in 1), sensitization and induction by first challenge and second challenge were performed.
    The drug was evaluated by removing the eye ball at 6 hours after the second challenge, preparing an optical microscopic specimen according to a conventional method, staining eosinophils by Luna staining, and counting and averaging the number of eosinophils infiltrated into conjunctiva with regard to each of 6 visible areas (one visible area being 0.04 mm2) of the vicinity of conjunctival lymphoid tissue. The drug was administered in the same manner as in 1).
    test group
  • physiological saline (control group)
  • 1.0% israpafant (instillation group)
  • 10 mg/kg israpafant p.o. (oral group)
  • 1 mg/kg mepyramine i.v. (intravenous injection group)
  • 1.0% israpafant + 1 mg/kg mepyramine i.v. (concurrent instillation group)
  • 10 mg/kg israpafant p.o.+1 mg/kg mepyramine i.v. (concurrent instillation group)
    • 5. Results and discussion 1) Suppressive effect (early phase reaction) against promotion of conjunctival vascular permeability
    Conjunctival dye-leakage at 30 minutes after the second challenge is shown in Fig. 2. In Fig. 2, each column shows mean± standard error (n=7 - 8). Significant difference from control group at *;p<0.05, **;p<0.01 (Dunnett's test). Significant difference from mepyramine group at #;p<0.05 (Student's test).
    The dye-leakage (µg/two eye balls) of the control group instilled with physiological saline was 34.5 µg but that of the israpafant instillation group and oral administration group was 24.7 µg and 25.3 µg, respectively. Thus, they did not show a significant suppressive effect. The dye-leakage of the mepyramine administration group was 17.5 µg, thus showing significant suppression of promotion of vascular permeability. In contrast, concurrent instillation group and oral concurrent group showed less (11.0 µg and 10.1 µg, respectively) dye-leakage than the single administration group, thus significantly suppressing promotion of vascular permeability.
    From the above results, it was suggested that israpafant was useful against early phase reaction when used concurrently with an antihistamic agent, because PAF is involved in the early phase reaction of allergic conjunctivitis.
    2) Suppressive effect (early phase reaction) against immediate allergic conjunctivitis signs
    The total score of conjunctivitis signs at 20 minutes after the second challenge is shown in Fig. 3. In Fig. 3, each column means mean ±standard error (n=8). Significant difference from control group at *;p<0.05 (Wilcoxon test).
    When compared to the total score of the physiological saline instilled control group, 1% israpafant instillation group showed significant decrease in the total score.
    From the above results, it was suggested that israpafant alleviated the conjunctivitis signs of immediate type allergy.
    3) Suppressive effect (late phase reaction) against eosinophil infiltration into conjunctiva
    The conjunctival eosinophil infiltration count at 6 hours after the second challenge is shown in Fig. 4. In Fig. 4, each column means mean±standard error (n=16). Significant difference from control group at *; p<0.05 (Dunnett's test).
    The eosinophil infiltration count (cell/0.04 mm2) of the control group was 95.3, but it was 71.8 in the israpafant instillation group, showing significant suppression of eosinophil infiltration. In contrast, the oral group showed no suppressive effect. In addition, the mepyramine group, the concurrent instillation group and concurrent oral administration group showed suppressive effect, but the effect of each group was almost the same, and no effect from the concurrent use of israpafant was found.
    From the above results, it was suggested that israpafant was useful against late phase reaction in view of significant suppression of eosinophil infiltration by single instillation. However, no effect was found by oral administration.
    Experimental Example 3 1. Object
    The effect was studied when used as an eye drop of israpafant against rat PAF conjunctivitis.
    2. Animal used
    Male Wistar rats weighing about 130 g purchased from Clea Japan, Inc. were used. They were bred at temperature 23±2°C and humidity 55±15%.
    3. Test drug
    Israpafant was suspended at 0.03, 0.1, 0.3 and 1.0%. Physiological saline was used for the control group.
    The formulation of the vehicle for an israpafant eye drop was as shown below, wherein the pH of the eye drop at each concentration was 7.0.
    sodium dihydrogenphosphate·2H2O 0.1 g
    sodium chloride 0.9 g
    polysorbate
    80 0.1 g
    distilled water 100 ml in total
    4. Test method
    PAF diluted to 4 µg/ml was administered to the upper subconjunctiva of the rat by 25 µl and at the same time, 0.5% Evans' blue (0.5 ml) was intravenously administered. Thirty minutes later, the dye-leakage part of the conjunctiva was excised and the dye was extracted with formamide, after which absorbance (625 nm) was measured. The test drug was administered by instillation (5 µl) to the eye at 1, 2 hours before subconjunctival induction of PAF.
    5. Results and Discussion
    The dye-leakage of each group is shown in Table 3.
    drug concentration (%) dose (µg) n amount of dye leakage (µg/site) inhibition (%)
    physiological saline - - 8 40.03±2.57 -
    israpafant 0.03 3 8 32.29±3.31 19.1
    0.1 10 8 28.17±1.42* 29.6
    0.3 30 7 23.37±2.56* 41.6
    1.0 100 7 18.74±2.20* 53.2
    Each value represents the mean±standard error.
    Significant difference from physiological saline at *;p<0.01 (Dunnett's test).
    The dye-leakage of the control group was 40.0 µg/site but israpafant showed a concentration-dependent suppressive effect, wherein the suppressive percentage at 0.03% - 1.0% concentration was 19.1%, 29.6%, 41.6% and 53.2%, showing significant difference at a concentration of 0.1% or greater. From the above results, israpafant showed a concentration-dependent suppressive effect against promotion of vascular permeability at conjunctival local site by PAF, demonstrating good penetration into a tissue of the present preparation.
    Experimental Example 4 1. Object
    The stability of israpafant suspension was studied.
    2. Drug and reagent
    Polysorbate 80 used met the standard of the Japan Pharmacopoeia.
    3. Test method
    The following israpafant suspension formulation was prepared. Polysorbate 80 was used as the suspending agent, phosphate buffer (pH 7) was used as the buffer, and sodium chloride was used as the isotonizing agent. The suspension was filled in glass ampoules by 5 ml and stored at 25, 40 and 60°C. The suspension was sampled with time (3 days later, one week later, 2 weeks later) and israpafant content was quantitatively determined by HPLC.
    israpafant 0.1 g
    polysorbate
    80 0.1 g
    sodium dihydrogenphosphate·2H2O 0.1 g
    sodium chloride 0.9 g
    distilled water 100 ml in total
    Quantitative Determination of israpafant - by HPLC HPLC conditions
  • column: YMCAM-302 (4.6×150 mm)
  • mobile phase: acetonitrile:0.1M ammonium acetate=87:13
  • detection: UV 244 nm
  • column temperature:35°C
  • flow rate: 0.7 ml/min
  • internal standard:1,3,5-triphenyl benzene
    • 4. Results and Discussion
    The results are shown in Table 4.
    temperature (°C) residual content (%)
    initial 3 days later 1 week later 2 weeks later
    25 100.0 (pH 6.97) - - 101.4 (pH 6.94)
    40 - - 99.7 (pH 6.94)
    60 97.3 (pH 6.96) 97.3 (pH 6.97) 100.3 (pH 6.96)
    80 99.3 (pH 6.97) - -
    As is evident from the Table, the 0.1% israpafant suspension after storage at 60°C for 2 weeks showed an israpafant residual content of 100.3%. The residual content after storage at 80°C for 3 days was 99.3%, demonstrating the stability of the 0.1% israpafant dispersion.
    Example 1 (Formulation Example of eye drop)
    Using the following ingredients, sodium dodecylsulfate, polysorbate 80, sodium dihydrogenphosphate dihydrate, boric acid and benzalkonium chloride were dissolved in sterile purified water. Using a pH adjusting agent, the pH was adjusted to about 7. Israpafant was added and the mixture was heated to about 70°C to allow dissolution. After cooling, the pH adjusting agent was used again to adjust the pH 7 to give an eye drop.
    israpafant 0.1 g
    sodium dodecylsulfate 0.65 g
    polysorbate
    80 3.25 g
    sodium dihydrogenphosphate dihydrate 0.1 g
    boric acid 1.6 g
    benzalkonium chloride 0.005 g
    sodium hydroxide q.s.
    sterile purified water amount to make the total amount 100 ml
    pH 7.0
    Example 2 (Formulation Example of nasal drop)
    Using the following ingredients and in the same manner as in Example 1, a nasal drop was obtained.
    israpafant 0.05 g
    polysorbate
    80 4.0 g
    sodium dihydrogenphosphate dihydrate 0.1 g
    sodium chloride 0.9 g
    benzalkonium chloride 0.01 g
    sodium hydroxide q.s.
    sterile purified water amount to make the total amount 100 ml
    pH 8.0
    Example 3 (Formulation Example of eye drop)
    Using the following ingredients and in the same manner as in Example 1, an eye drop was obtained.
    israpafant 0.05 g
    sodium octanesulfonate 0.5 g
    polysorbate
    80 3.35 g
    sodium dihydrogenphosphate dihydrate 0.1 g
    sodium chloride 0.9 g
    benzalkonium chloride 0.005 g
    sodium hydroxide q.s.
    sterile purified water amount to make the total amount 100 ml
    pH 7.0
    Example 4 (Formulation Example of eye drop)
    Using the following ingredients and in the same manner as in Example 1, an eye drop was obtained.
    israpafant 0.05 g
    sodium pentanesulfonate 0.5 g
    polysorbate
    80 4.15 g
    sodium dihydrogenphosphate dihydrate 0.1 g
    conc. glycerol 2.6 g
    benzalkonium chloride 0.005 g
    sodium hydroxide q.s.
    sterile purified water amount to make the total amount 100 ml
    pH 7.0
    Example 5 (Formulation Example of eye drop)
    Using the following ingredients and in the same manner as in Example 1, an eye drop was obtained.
    israpafant 0.1 g
    SDS 0.65 g
    polysorbate
    80 3.25 g
    sodium acetate 0.1 g
    sodium chloride 0.9 g
    methyl p-hydroxybenzoate 0.026 g
    propyl p-hydroxybenzoate 0.014 g
    hydrochloric acid q.s.
    sterile purified water amount to make the total amount 100 ml
    pH 5.0
    Example 6
    israpafant 0.1 g
    polysorbate
    80 0.1 g
    monosodium phosphate dihydrate 0.1 g
    sodium chloride 0.9 g
    benzalkonium chloride 0.005 g
    sodium hydroxide appropriate amount
    sterile purified water amount to make the total amount 100 ml
    pH 7.0
    Example 7
    israpafant 1.0 g
    HPMC 0.001 g
    sodium dihydrogenphosphate dihydrate 0.1 g
    sodium chloride 0.9 g
    benzalkonium chloride 0.005 g
    sodium hydroxide appropriate amount
    sterile purified water amount to make the total amount 100 ml
    pH 7.0
    Example 8
    israpafant 0.1 g
    HCO-60 0.1 g
    sodium dihydrogenphosphate dihydrate 0.1 g
    sodium chloride 0.9 g
    benzalkonium chloride 0.005 g
    sodium hydroxide appropriate amount
    sterile purified water amount to make the total amount 100 ml
    pH 7.0
    Example 9
    israpafant 1.0 g
    HPMC 0.01 g
    sodium dihydrogenphosphate dihydrate 0.1 g
    sodium chloride 0.9 g
    methyl p-hydroxybenzoate 0.026 g
    propyl p-hydroxybenzoate 0.014 g
    sodium hydroxide appropriate amount
    sterile purified water amount to make the total amount 100 ml
    pH 5.0
    Example 10
    israpafant 1.0 g
    HPMC 0.01 g
    boric acid 1.6 g
    benzalkonium chloride 0.005 g
    sodium hydroxide appropriate amount
    sterile purified water amount to make the total amount 100 ml
    pH 7.0
    Example 11
    israpafant 0.1 g
    tyloxapol 0.1 g
    sodium dihydrogenphosphate dihydrate 0.1 g
    sodium chloride 0.9 g
    benzalkonium chloride 0.005 g
    sodium hydroxide appropriate amount
    sterile purified water amount to make the total amount 100 ml
    pH 7.0
    Example 12
    israpafant 0.1 g
    SDS 0.001 g
    sodium dihydrogenphosphate dihydrate 0.1 g
    boric acid 1.6 g
    benzalkonium chloride 0.005 g
    sodium hydroxide appropriate amount
    sterile purified water amount to make the total amount 100 ml
    pH 7.0
    Example 13
    israpafant 1.0 g
    methylcellulose 0.001 g
    sodium dihydrogenphosphate dihydrate 0.1 g
    sodium chloride 0.9 g
    benzalkonium chloride 0.005 g
    sodium hydroxide appropriate amount
    sterile purified water amount to make the total amount 100 ml
    pH 7.0
    Example 14
    israpafant 0.1 g
    methylcellulose 0.1 g
    sodium acetate 0.1 g
    conc. glycerol 2.6 g
    methyl p-hydroxybenzoate 0.026 g
    propyl p-hydroxybenzoate 0.014 g
    chlorobutanol 0.2 g
    sodium hydroxide appropriate amount
    sterile purified water amount to make the total amount 100 ml
    pH 5.0
    Example 15
    israpafant 0.1 g
    sucrose fatty acid ester 0.05 g
    sodium dihydrogenphosphate dihydrate 0.1 g
    sodium chloride 0.9 g
    benzalkonium chloride 0.005 g
    sodium hydroxide appropriate amount
    sterile purified water amount to make the total amount 100 ml
    pH 7.0
    Example 16
    israpafant 0.1 g
    polysorbate
    80 0.005 g
    PVP K30 0.2 g
    sodium dihydrogenphosphate dihydrate 0.1 g
    sodium chloride 0.9 g
    benzalkonium chloride 0.005 g
    sodium hydroxide appropriate amount
    sterile purified water amount to make the total amount 100 ml
    pH 7.0
    Example 17
    israpafant 1.0 g
    HPMC(2910) 0.004 g
    sodium dihydrogenphosphate dihydrate 0.1 g
    sodium chloride 0.9 g
    benzalkonium chloride 0.005 g
    sodium hydroxide appropriate amount
    sterile purified water amount to make the total amount 100 ml
    pH 7.0
    Industrial Applicability
    The aqueous agent of the present invention shows superior therapeutic effect when locally administered as an eye drop or a nasal drop for allergic conjunctivitis, allergic rhinitis, venal conjunctivitis, conjunctival allergy caused by contact lens (giant papillary conjunctivitis), phlyctenular conjunctivitis, contact blepharoconjunctivitis, Sjögren's syndrome, multiple corneal infiltration, keratitis disciformis, stromal keratitis, endothelium keratitis, episcleritis, scleritis, uveitis, retinal vasculitis, papillary vasulitis, optic neuritis, eosinophilic granuloma, rejection associated with keratoplastry, eye itching, sneeze, nose itching, hypersensitivity of the nose, nose vestibule eczema, anterior rhinitis sicca, nasal obstruction and the like.
    This application is based on patent application Nos. 137061/1997 and 154474/1997 filed in Japan, the contents of which are hereby incorporated by reference.

    Claims (20)

    1. An aqueous agent containing israpafant, which is expressed by the formula (I):
      Figure 00280001
    2. The aqueous agent of claim 1, wherein the israpafant (I) has a concentration of not less than 0.01 w/v%.
    3. The aqueous agent of claim 2, wherein the aqueous agent is an eye drop or nasal drop.
    4. The aqueous agent of claim 3, wherein the eye drop or nasal drop is an aqueous solution containing israpafant (I).
    5. The aqueous agent of claim 4, wherein the israpafant (I) has a concentration of 0.01 - 0.1 w/v%.
    6. The aqueous agent of claim 5, further comprising a surfactant.
    7. The aqueous agent of claim 6, wherein the surfactant has a concentration of 0.5 - 10 w/v%.
    8. The aqueous agent of claim 7, wherein the surfactant is at least one member selected from the group consisting of a cationic surfactant, an anionic surfactant and a nonionic surfactant.
    9. The aqueous agent of claim 3, wherein the eye drop or nasal drop is a suspension containing israpafant (I).
    10. The aqueous agent of claim 9, wherein the israpafant has a concentration of 0.01 - 2 w/v%.
    11. The aqueous agent of claim 10, further comprising a suspending agent.
    12. The aqueous agent of claim 11, wherein the suspending agent is at least one member selected from a surfactant and a water soluble polymer.
    13. The aqueous agent of claim 12, wherein the surfactant has a concentration of 0.0001 - 0.1 w/v%.
    14. The aqueous agent of claim 13, wherein the surfactant is at least one member selected from a nonionic surfactant and an anionic surfactant.
    15. The aqueous agent of claim 12, wherein the water soluble polymer has a concentration of 0.00001 - 0.5 w/v%.
    16. The aqueous agent of claim 15, wherein the water soluble polymer is a water soluble cellulose derivative.
    17. The aqueous agent of claim 16, wherein the water soluble cellulose derivative is at least one cellulose derivative selected from hydroxypropylmethylcellulose, carboxymethylcellulose and methylcellulose.
    18. The aqueous agent of claim 17, wherein the agent comprises israpafant (I) in a proportion of 0.1 - 1 w/v% and hydroxypropylmethylcellulose in the weight ratio to israpafant (I) of 0.001 - 0.01:1.
    19. A method for producing an aqueous solution of israpafant, comprising dissolving israpafant of the formula (I):
      Figure 00300001
      in water in the presence of a surfactant.
    20. A method for producing a suspension of israpafant, comprising suspending israpafant of the formula (I):
      Figure 00300002
      in water in the presence of a suspending agent.
    EP98921787A 1997-05-27 1998-05-22 AQUEOUS PREPARATIONS CONTAINING ISRAPAFANT Withdrawn EP1004309A4 (en)

    Applications Claiming Priority (5)

    Application Number Priority Date Filing Date Title
    JP13706197 1997-05-27
    JP13706197 1997-05-27
    JP15447497 1997-05-27
    JP15447497 1997-05-27
    PCT/JP1998/002275 WO1998053828A1 (en) 1997-05-27 1998-05-22 Israpafant-containing water-base preparations

    Publications (2)

    Publication Number Publication Date
    EP1004309A1 true EP1004309A1 (en) 2000-05-31
    EP1004309A4 EP1004309A4 (en) 2001-01-17

    Family

    ID=26470488

    Family Applications (1)

    Application Number Title Priority Date Filing Date
    EP98921787A Withdrawn EP1004309A4 (en) 1997-05-27 1998-05-22 AQUEOUS PREPARATIONS CONTAINING ISRAPAFANT

    Country Status (4)

    Country Link
    EP (1) EP1004309A4 (en)
    KR (1) KR20010013072A (en)
    CA (1) CA2291735A1 (en)
    WO (1) WO1998053828A1 (en)

    Cited By (2)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    WO2002076432A3 (en) * 2001-03-26 2002-12-12 Novartis Ag Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
    US8791154B2 (en) 2011-05-19 2014-07-29 Alcon Research, Ltd. High concentration olopatadine ophthalmic composition

    Families Citing this family (1)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US7355237B2 (en) 2004-02-13 2008-04-08 Sandisk Corporation Shield plate for limiting cross coupling between floating gates

    Family Cites Families (8)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    JPH01156982A (en) * 1986-11-17 1989-06-20 Yoshitomi Pharmaceut Ind Ltd Thienotriazolodiazepine derivatives
    JP2902459B2 (en) * 1990-08-28 1999-06-07 裕 水島 Fat emulsion containing PAF antagonist
    CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
    DE4128581A1 (en) * 1991-08-28 1993-03-04 Boehringer Ingelheim Kg Thieno (3,2-f) (1,2,4)triazolo (4,3-a)(1,4) diazepine derivs. - useful for treatment and prevention of allergic rhinitis, in nasal spray, avoiding side effects
    US5686479A (en) * 1991-12-11 1997-11-11 Yoshitomi Pharmaceutical Industries, Ltd. Immunosuppressive drug
    DE4201147A1 (en) * 1992-01-17 1993-07-22 Boehringer Ingelheim Kg USE OF PAF ANTAGONISTS HETRAZEPINOIDER STRUCTURE FOR THE TREATMENT OF ALLERGIC RHINITIS AND RELATED INDICATIONS
    JP3781792B2 (en) * 1993-12-27 2006-05-31 千寿製薬株式会社 Ophthalmic suspension containing difluprednate
    FR2715566B1 (en) * 1994-02-03 1996-03-08 Synthelabo Concentrated aqueous solutions of argatroban.

    Cited By (3)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    WO2002076432A3 (en) * 2001-03-26 2002-12-12 Novartis Ag Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
    US8791154B2 (en) 2011-05-19 2014-07-29 Alcon Research, Ltd. High concentration olopatadine ophthalmic composition
    US9533053B2 (en) 2011-05-19 2017-01-03 Alcon Research, Ltd. High concentration olopatadine ophthalmic composition

    Also Published As

    Publication number Publication date
    KR20010013072A (en) 2001-02-26
    EP1004309A4 (en) 2001-01-17
    CA2291735A1 (en) 1998-12-03
    WO1998053828A1 (en) 1998-12-03

    Similar Documents

    Publication Publication Date Title
    US8969385B2 (en) Ocular formulations of norketotifen
    EP2346520B1 (en) Curcuminoids and its metabolites for the application in ocular diseases
    EP1885336B1 (en) Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
    US20010049366A1 (en) Topical solution formulations containing an antibiotic and a corticosteroid
    SK147493A3 (en) Antialergic substances for the use in ophthalmologic and otorhynologic
    JP2012521412A (en) Curcuminoids and their metabolites for application in nasal allergic diseases
    EP0659433B1 (en) Ophthalmic suspension containing diflupredonate
    EP1906916B1 (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
    EP0996442B1 (en) Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
    JP3781792B2 (en) Ophthalmic suspension containing difluprednate
    EP1004309A1 (en) Israpafant-containing water-base preparations
    RS67054B1 (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
    CN116867480A (en) Methods of ocular delivery of roflumilast
    WO2005101982A2 (en) A stable ophthalmic composition
    JPH1192368A (en) Aqueous liquid agent containing benzopyran derivative as main component
    US20220233636A1 (en) Aqueous suspensions of cyclosporin
    JPWO2001087303A1 (en) Water-based liquid
    CN101272765A (en) Photostable pharmaceutical composition comprising brivudine for the treatment of herpetic keratitis
    JPWO1998053828A1 (en) Israpafant-containing aqueous solution
    JP2002128671A (en) Ophthalmic solution
    CN120204128A (en) Ophthalmic pharmaceutical composition and use thereof
    EP0719553A1 (en) Pharmaceutical composition for topical administration to the eye for treating allergic conjunctivitis
    WO1995025518A1 (en) Aqueous solution of levocabastine for ophthalmic use
    KR20250057103A (en) Pharmaceutical composition comprising roflumilast and a solvent capable of dissolving a large amount of the drug
    US20030144335A1 (en) Preventive or remedial agent for allergic disease and medical water-based liquid preparation, eye drop, and nasal drop

    Legal Events

    Date Code Title Description
    PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

    Free format text: ORIGINAL CODE: 0009012

    17P Request for examination filed

    Effective date: 19991215

    AK Designated contracting states

    Kind code of ref document: A1

    Designated state(s): DE ES FR GB IT

    A4 Supplementary search report drawn up and despatched

    Effective date: 20001206

    AK Designated contracting states

    Kind code of ref document: A4

    Designated state(s): DE ES FR GB IT

    RIC1 Information provided on ipc code assigned before grant

    Free format text: 7A 61K 31/55 A, 7A 61K 9/06 B, 7C 07D 495/14 -

    RAP1 Party data changed (applicant data changed or rights of an application transferred)

    Owner name: WELFIDE CORPORATION

    Owner name: SENJU PHARMACEUTICAL CO., LTD.

    RIN1 Information on inventor provided before grant (corrected)

    Inventor name: OTORI, AKIRA

    Inventor name: OGAWA, TAKAHIRO

    Inventor name: YASUEDA, SHINICHI

    Inventor name: TERAI, TADASHI

    RAP1 Party data changed (applicant data changed or rights of an application transferred)

    Owner name: MITSUBISHI PHARMA CORPORATION

    Owner name: SENJU PHARMACEUTICAL CO., LTD.

    17Q First examination report despatched

    Effective date: 20030108

    STAA Information on the status of an ep patent application or granted ep patent

    Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

    18D Application deemed to be withdrawn

    Effective date: 20021203